Who are HX575 epoetin alfa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HX575 epoetin alfa (Sandoz).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hx575-epoetin-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HX575 epoetin alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HX575 epoetin alfa (HX575 epoetin alfa) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA) / Biosimilar. Area: Hematology / Oncology.

phase 3 Erythropoiesis-stimulating agent (ESA) / Biosimilar Erythropoietin receptor (EPOR) Hematology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HX575 epoetin alfa (HX575 epoetin alfa) — Sandoz. HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HX575 epoetin alfa TARGET	HX575 epoetin alfa	Sandoz	phase 3	Erythropoiesis-stimulating agent (ESA) / Biosimilar	Erythropoietin receptor (EPOR)
HX575 epoetin alfa (Sandoz)	HX575 epoetin alfa (Sandoz)	Sandoz	phase 3	Erythropoiesis-stimulating agent (ESA) / Biosimilar	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) / Biosimilar class)

Sandoz · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HX575 epoetin alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/hx575-epoetin-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab